featured
Bortezomib, Thalidomide, and Dexamethasone Followed by Double Auto-HSCT for Newly Diagnosed Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Bortezomib, Thalidomide, and Dexamethasone Followed by Double Autologous Haematopoietic Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (GIMEMA-MMY-3006): Long-Term Follow-Up Analysis of a Randomised Phase 3, Open-Label Study
Lancet Haematol 2020 Dec 01;7(12)e861-e873, P Tacchetti, L Pantani, F Patriarca, MT Petrucci, E Zamagni, L Dozza, M Galli, F Di Raimondo, C Crippa, M Boccadoro, S Barbato, P Tosi, F Narni, V Montefusco, N Testoni, A Spadano, C Terragna, N Pescosta, G Marzocchi, C Cellini, P Galieni, S Ronconi, M Gobbi, L Catalano, A Lazzaro, G De Sabbata, C Cangialosi, F Ciambelli, P Musto, F Elice, M CavoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.